The bridging concept: Optimizing dose for phase II/III in Alzheimer's disease

Neurodegeneration

Volumn 5, Issue 4, 1996, Pages 511-514

  Cutler, Neal R ^a,b   Sramek, John J ^a,b   Kilborn, John R ^a  

^a International Clinical Trials   (United Kingdom)

^b CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Alzheimer's disease; Bridging treatment; Clinical trials

Indexed keywords

BESIPIRDINE; HEPTYLSTIGMINE TARTRATE; MIRAMELINE; TACRINE; UNCLASSIFIED DRUG; VELNACRINE; XANOMELINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; METHODOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030512323     PISSN: 10558330     EISSN: None     Source Type: Journal    
DOI: 10.1006/neur.1996.0071     Document Type: Conference Paper

References (16)

1. Cutler NR, Murphy MJ, Nash RJ, Prior PL (1990) Clinical safety, tolerance, and plasma levels of HP 029 in Alzheimer's disease. J Clin Pharmacol 30:556-561
2. Cutler NR, Sramek JJ (1995a) Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 48:421-428
3. Cutler NR, Sramek JJ (1995b) The target population in phase I clinical trials of cholinergic compounds in Alzheimer's disease: the role of the 'bridging study.' Alzheimer Dis Assoc Disord 9:139-145
4. Cutler NR, Sramek JJ, Veroff AE (1994) Alzheimer's Disease: Optimizing Drug Development Strategies. Chichester: John Wiley & Sons, Ltd
5. Geller NL (1984) Design of phase I and II clinical trials in cancer: a statistician's view. Cancer Invest 2:483-491
6. Goldberg MR, Barchowsky A, McCrea J, Ben-Maimon C, Capra N, Fitzpatrick V, Bjornsson TD (1991) Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteer study. Presented at: Second International Springfield Symposium on Advances in Alzheimer Therapy
7. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon CI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985-991
8. Puri SK, Ho I, Hsu R, Lassman HB (1990) Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. J Clin Pharmacol 30:948-955
9. Puri SK, Hsu RS, Ho I, Lassman HB (1989) Single dose safety, tolerance and pharmacokinetics of HP029 in healthy young men: A potential Alzheimer agent. J Clin Pharmacol 29:278-284
10. Puri SK, Hsu R, Ho I, Lassman HB (1988) Single-dose safety, tolerance, and pharmacokinetics of HP029 in elderly men: a potential Alzheimer agent. Curr Ther Res 44:766-780
11. Reece PA, Bockbrader H, Sedman AJ (1992) Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979. Clin Exp Pharmacol Physiol 21 (Suppl):58
12. Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR (1994) A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 56:319-326
13. Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, Cutler NR (1995a) The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 35:800-806
14. Sramek JJ, Sedman, AJ, Reece PA, Underwood B, Seifert RD, Bockbrader H, Cutler NR (1995b) Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 57:503-510
15. Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, Cutler NR (1995c) A 'bridging' (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. Life Sci 57:1241-1248
16. Tollefson GD, Bodick NC, Shannon HC (1994) Xanomeline: a potent and specific M1 agonist in the treatment of Alzheimer's disease. Presented at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12-16, 1994